PF-Atlas › Clinical Trials › ISM001-055

Rentosertib TNIK Inhibitor in IPF — Phase IIa

Rentosertib · TNIK Inhibition (AI-discovered) · Phase 2

Registry ID
ISM001-055
Phase
Phase 2
Status
Completed
Drug / intervention
Rentosertib
Mechanism
TNIK Inhibition (AI-discovered)
Sponsor
Insilico Medicine
Start
2023-01

About this trial

Rentosertib is evaluated in ISM001-055, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Insilico Medicine, targeting tnik inhibition (ai-discovered). Current status: Completed.

View ISM001-055 on ClinicalTrials.gov →

Explore related

Rentosertib / ISM001-055 — Treatment profileAll Rentosertib trialsTNIK Inhibition (AI-discovered) mechanismAll IPF trials
Medical disclaimer. This page summarizes public trial data for ISM001-055 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.